Overview

This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:
0

Participant gender:
All

Summary

The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081100 and who wish to receive open-label pregabalin therapy.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatments:

Pregabalin

Criteria

Inclusion Criteria:

- Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol
A0081100, and must have received pregabalin/placebo under double-blind conditions.

Exclusion Criteria:

- Patients may not participate in the study if they experienced a serious adverse event
during the previous fibromyalgia Study A0081100 which was determined to be related to
the study medication by the investigator or the sponsor.